Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2014, Article ID 358567, 3 pages
http://dx.doi.org/10.1155/2014/358567
Case Report

Lung Sarcoidosis in Etanercept Treated Rheumatoid Arthritis Patient: A Case Report and Review of the Literature

Mount Sinai School of Medicine, Queens Hospital Center, Jamaica, NY 11432, USA

Received 18 January 2014; Accepted 23 June 2014; Published 3 July 2014

Academic Editor: Suleyman Serdar Koca

Copyright © 2014 Supat Thongpooswan and Adriana Abrudescu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Moustou, A. Matekovits, C. Dessinioti, C. Antoniou, P. P. Sfikakis, and A. J. Stratigos, “Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review,” Journal of the American Academy of Dermatology, vol. 61, no. 3, pp. 486–504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. E. Furst, “The risk of infections with biologic therapies for rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 39, no. 5, pp. 327–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Caspersen, M. Elkjaer, L. Riis et al., “Infliximab forinflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality,” Clinical Gastroenterology and Hepatology, vol. 6, no. 11, pp. 1212–1217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. A. Antoniu, “Targeting the TNF-α pathway in sarcoidosis,” Expert Opinion on Therapeutic Targets, vol. 14, no. 1, pp. 21–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Callejas-Rubio, L. López-Pérez, and N. Ortego-Centeno, “Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis,” Therapeutics and Clinical Risk Management, vol. 4, no. 6, pp. 1305–1313, 2008. View at Google Scholar · View at Scopus
  6. R. P. Baughman, M. Drent, M. Kavuru et al., “Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement,” The American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 795–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Baughman, E. E. Lower, D. A. Bradley, L. A. Raymond, and A. Kaufman, “Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial,” Chest, vol. 128, no. 2, pp. 1062–1067, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Utz, A. H. Limper, S. Kalra et al., “Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis,” Chest, vol. 124, no. 1, pp. 177–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Gifre, V. Ruiz-Esquide, A. Xaubet, J. A. Gómez-Puerta, M. V. Hernández, and R. Sanmartí, “Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review,” Archivos de Bronconeumología, vol. 47, no. 4, pp. 208–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kudrin, E. R. Chilvers, A. Ginawi et al., “Sarcoid-like granulomatous disease following etanercept treatment for rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 3, pp. 648–649, 2007. View at Google Scholar · View at Scopus
  11. K. Verschueren, E. van Essche, P. Verschueren, V. Taelman, and R. Westhovens, “Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients,” Clinical Rheumatology, vol. 26, no. 11, pp. 1969–1971, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. C. I. Daïen, A. Monnier, P. Claudepierre et al., “Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases,” Rheumatology, vol. 48, no. 8, pp. 883–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Ishiguro, N. Takayanagi, K. Kurashima et al., “Development of sarcoidosis during etanercept therapy,” Internal Medicine, vol. 47, no. 11, pp. 1021–1025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. R. Clementine, J. Lyman, J. Zakem, J. Mallepalli, S. Lindsey, and R. Quinet, “Tumor necrosis factor-α antagonist-induced sarcoidosis,” Journal of Clinical Rheumatology, vol. 16, no. 6, pp. 274–279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Kanellopoulou, A. Filiotou, H. Kranidioti, and S. P. Dourakis, “Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature,” Clinical Rheumatology, vol. 30, no. 4, pp. 581–583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. S. Wallis and S. Ehlers, “Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab,” Seminars in Arthritis and Rheumatism, vol. 34, no. 5, pp. 34–38, 2005. View at Publisher · View at Google Scholar · View at Scopus